Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs FuelCell Energy Inc (FCEL) Price & Performance

BioNTech SE - ADRTrade
FuelCell Energy IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs FuelCell Energy Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while FuelCell Energy Inc trades at $21.65 (market cap $1.54B). The key difference: BioNTech SE - ADR is far larger — about 15.1× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXFCEL
Market Cap
$23.31B$1.54B
Sector
HealthIndustrials
52-Week High
$119.34$36.01
52-Week Low
$83.89$3.92
Enterprise Value
$6.60B$1.38B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

FuelCell Energy Inc

FCEL trades at $22.16, up 11.75% in the past 24 hours, but remains in a bearish technical trend. The company continues to post significant losses, with a net income margin of -132.41% in 2025, despite recent revenue growth to $158.16M. Analyst sentiment is divided with a 45% buy and 45% hold consensus, and a price target of $20.75. Recent news highlights partnerships and volatility within the hydrogen sector.

The outlook is clouded by persistent unprofitability and negative cash flow from operations, posing substantial risk. Upside potential hinges on successful commercialization of technology and sector tailwinds, but the stock faces headwinds from execution challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About FuelCell Energy Inc

FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.

Read more on FCEL